A cover letter is required for consideration for this position and should be attached as the first page of your resume. The cover letter should address your specific interest in the position and outline skills and experience that directly relate to this position.
The Castro/Lowenstein Laboratory within the Department of Neurosurgery is accepting applications for a Post-Doctoral Fellowship position funded by NIH. The successful candidate will join an exciting and productive research team focused on elucidating the molecular and physical basis of brain tumor growth, invasion and the response to novel therapeutics. The project will study the molecular and cellular mechanisms involved in the epigenetic remodeling of the tumor immune microenvironment and how this impacts tumor progression and the response to immune mediated therapies. The project will also investigate the mechanisms that mediate genomic instability, chromatin structure and the DNA repair machinery in genetically engineered brain cancer models and samples from human patients, with the aim of uncovering novel therapeutic targets that can be readily translated into the clinical arena. The project will also investigate the mechanisms that mediate genomic instability, chromatin structure and the DNA repair machinery in genetically engineered brain cancer models and samples from human patients, with the aim of uncovering novel therapeutic targets that can be readily translated into the clinical arena. The project will also utilize state-of-the-art "omics" technologies such as Single Cell RNASeq, ChIP-Seq, ATAC-Seq, as well as advanced Bioinformatics. The project has a strong translational component focusing on the development and implementation of novel therapeutic approaches in human clinical trials for brain cancer; these include gene therapy strategies, small molecules, and nano-technologies. The lab is utilizing novel gene therapy and combination therapies and exploring ways to translate the research into novel Phase I clinical trials for brain cancer.
Haase S. et al. H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models. Journal of Clinical Investigation. September 2022. DOI: 10.1172/JCI154229
Kadiyala K. et al. Inhibition of 2-Hydroxyglutarate Elicits Metabolic-reprogramming and Mutant IDH1 Glioma Immunity in mice. Journal of Clinical Investigation. 2020 Dec 17:139542. doi: 10.1172/JCI139542.
Alghamri M.S. et al. G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy. Science Advances. 2021 Oct;7(40):eabh3243. doi: 10.1126/sciadv.abh3243. Epub 2021 Sep 29. PMID: 34586841
Nunez F.J. et al. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. Science Translational Medicine. 2019 Feb 13;11(479):eaaq1427. doi: 10.1126/scitranslmed.aaq1427. PMID: 30760578
Michigan Medicine improves the health of patients, populations and communities through excellence in education, patient care, community service, research and technology development, and through leadership activities in Michigan, nationally and internationally. Our mission is guided by our Strategic Principles and has three critical components; patient care, education and research that together enhance our contribution to society.
Positions that are eligible for hybrid or mobile/remote work mode are at the discretion of the hiring department. Work agreements are reviewed annually at a minimum and are subject to change at any time, and for any reason, throughout the course of employment. Learn more about the work modes.
Michigan Medicine conducts background screening and pre-employment drug testing on job candidates upon acceptance of a contingent job offer and may use a third party administrator to conduct background screenings. Background screenings are performed in compliance with the Fair Credit Report Act. Pre-employment drug testing applies to all selected candidates, including new or additional faculty and staff appointments, as well as transfers from other U-M campuses.
Job openings are posted for a minimum of seven calendar days. The review and selection process may begin as early as the eighth day after posting. This opening may be removed from posting boards and filled anytime after the minimum posting period has ended.
The University of Michigan is an equal opportunity/affirmative action employer.
